- Previous Close
471.70 - Open
464.60 - Bid 399.00 x --
- Ask 447.80 x --
- Day's Range
425.00 - 466.80 - 52 Week Range
282.00 - 613.50 - Volume
221 - Avg. Volume
3,159 - Market Cap (intraday)
8.807B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
41.57 - EPS (TTM)
10.26 - Earnings Date May 7, 2025
- Forward Dividend & Yield 6.00 (2.12%)
- Ex-Dividend Date Oct 13, 2023
- 1y Target Est
--
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. In addition, the company provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
chemometec.comRecent News: 0DZ0.IL
View MorePerformance Overview: 0DZ0.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0DZ0.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0DZ0.IL
View MoreValuation Measures
Market Cap
7.40B
Enterprise Value
7.14B
Trailing P/E
43.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.14
Price/Book (mrq)
12.41
Enterprise Value/Revenue
15.54
Enterprise Value/EBITDA
30.11
Financial Highlights
Profitability and Income Statement
Profit Margin
40.20%
Return on Assets (ttm)
24.86%
Return on Equity (ttm)
40.14%
Revenue (ttm)
444.4M
Net Income Avi to Common (ttm)
178.67M
Diluted EPS (ttm)
10.26
Balance Sheet and Cash Flow
Total Cash (mrq)
316.57M
Total Debt/Equity (mrq)
1.34%
Levered Free Cash Flow (ttm)
71.04M